05/19 | Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Progr.. | BU |
05/17 | Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Car.. | BU |
05/17 | Gilead Sciences, Inc. - FDA Lifts Clinical Hold on Investigational Lenacapavir for the .. | AQ |
05/16 | FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention.. | BU |
05/05 | GILEAD SCIENCES, INC. : Submission of Matters to a Vote of Security Holders, Financial Sta.. | AQ |
05/04 | GILEAD SCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND .. | AQ |
05/02 | Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Kille.. | BU |
04/28 | GILEAD SCIENCES : View First Quarter 2022 Supplementary Info | PU |
04/28 | GILEAD SCIENCES : ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS - Form 8-K | PU |
04/28 | GILEAD SCIENCES : View First Quarter 2022 Summary of Remarks | PU |
04/28 | GILEAD SCIENCES : View First Quarter 2022 Earnings Release | PU |
04/28 | GILEAD : Q1 Earnings Snapshot | AQ |
04/28 | Gilead Sciences Announces First Quarter 2022 Financial Results | BU |
04/26 | Gilead Sciences to Present at Upcoming Investor Conferences | BU |
04/26 | Gilead Sciences, Inc. - Veklury (Remdesivir) is First and Only Approved Treatment for P.. | AQ |
04/25 | Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under.. | BU |
04/25 | Several New Studies Presented at ECCMIC 2022 Confirm Veklury (Remdesivir) Activity in T.. | AQ |
04/24 | Several New Studies Presented at ECCMIC 2022 Confirm Veklury® (Remdesivir) Activity in .. | BU |
04/22 | Gilead Statement on WHO Recommendation of Veklury (Remdesivir) and Acceleration of Preq.. | AQ |
04/21 | GILEAD SCIENCES : Statement on WHO Recommendation of Veklury® (Remdesivir) and Acceleratio.. | PU |
04/19 | Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturin.. | BU |
04/14 | Gilead Sciences to Release First Quarter 2022 Financial Results on Thursday, April 28, .. | BU |
04/13 | FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies | AQ |
04/12 | Gilead Sciences, Inc. - FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studi.. | AQ |
04/11 | FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies | BU |
04/04 | Yescarta Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment o.. | AQ |
04/01 | Yescarta® Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment .. | BU |
03/28 | Gilead Sciences Announces $24 Million in Grants to Help End the HIV Epidemic for Everyo.. | BU |
03/24 | GILEAD SCIENCES : Annual Report Supplement - Corporate Information | PU |
03/16 | Biopharma Stocks Targeting Crohn's Disease In $13.7 Billion Market (STAB, ARNA, GILD an.. | AQ |
03/15 | GILEAD SCIENCES : Implements Contract Pharmacy Integrity Initiative for Branded Hepatitis .. | PU |
03/11 | CAPITALGAINSREPORT : Biopharma Stocks Outperforming In $471 Billion Market (STAB, GILD, EX.. | AQ |
03/09 | GILEAD SCIENCES : to Expand Footprint in Oceanside | PU |
03/07 | GILEAD SCIENCES : PHASE 3 TROPiCS-02 STUDY MET THE PRIMARY ENDPOINT OF PROGRESSION- FREE S.. | PU |
03/07 | Phase 3 TROPiCS-02 Study Met the Primary Endpoint of Progression-Free Survival in Late-.. | BU |
03/07 | GILEAD SCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form .. | AQ |
03/02 | Gilead Receives Complete Response Letter From U.S. FDA for Investigational Lenacapavir .. | AQ |
03/01 | Gilead Receives Complete Response Letter From U.S. FDA for Investigational Lenacapavir .. | BU |
02/23 | GILEAD SCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
.. | AQ |
02/17 | Gilead Sciences, Inc. - New Clinical Data Support the Sustained Efficacy of Long-acting.. | AQ |
02/16 | New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead's I.. | BU |
02/14 | Gilead Sciences, Inc. - Veklury (Remdesivir) Retains Antiviral Activity Against Omicron.. | AQ |
02/14 | Gilead Sciences, Inc. - Biktarvy Demonstrates High Efficacy and Durable Viral Suppressi.. | AQ |
02/14 | Gilead Sciences, Inc. - Phase 2/3 Interim Data Evaluating the Safety, Tolerability and .. | AQ |
02/11 | GILEAD SCIENCES : View Q4 2021 Resource Book | PU |
02/11 | Phase 2/3 Interim Data Evaluating the Safety, Tolerability and Clinical Outcomes of Vek.. | BU |
02/11 | Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression at Five Years, in Tr.. | BU |
02/11 | Veklury® (Remdesivir) Retains Antiviral Activity Against Omicron, Delta and Other Emerg.. | BU |
02/10 | Takeda's Ramona Sequeira Becomes Board Chair of PhRMA | AQ |
02/09 | Gilead Expands Availability of Veklury (remdesivir) to Non-Hospital Outpatient Faciliti.. | AQ |
02/09 | Gilead Sciences, Inc. to Help Dream Foundation Fulfill the Final Dreams of More Than 85.. | AQ |
02/08 | GILEAD SCIENCES : Expands Availability of Veklury® (remdesivir) to Non-Hospital Outpatient.. | PU |
02/08 | Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressin.. | BU |
02/04 | GILEAD SCIENCES : Expands Availability of Veklury® (remdesivir) to Non-Hospital Outpatient.. | PU |
02/03 | Gilead Sciences to Present at Upcoming Investor Conferences | BU |
02/02 | Alphabet, Brinker International rise; PayPal, Gilead fall | AQ |
02/02 | GSK announces settlement between ViiV Healthcare and Gilead Sciences, Inc. resolving li.. | AQ |
02/01 | GILEAD SCIENCES : View Q4 & Full Year 2021 Summary of Remarks | PU |
02/01 | GILEAD : Q4 Earnings Snapshot | AQ |
02/01 | GILEAD SCIENCES : View Q4 & Full Year 2021 Supplementary Info | PU |
02/01 | GILEAD SCIENCES : Fourth Quarter 2021 Supplementary Info | PU |
02/01 | GILEAD SCIENCES : ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS - Form 8-K | PU |
02/01 | GILEAD SCIENCES : Announces Global Resolution of Bictegravir Patent Dispute with ViiV Heal.. | PU |
02/01 | GILEAD SCIENCES : View Q4 & Full Year 2021 Earnings Release | PU |
02/01 | GILEAD SCIENCES : View Q4 & Full Year 2021 Presentation | PU |
02/01 | Gilead Sciences Announces 2.8 Percent Increase in First Quarter 2022 Dividend | BU |
02/01 | GILEAD SCIENCES INC : Results of Operations and Financial Condition (form 8-K) | AQ |
02/01 | Gilead Sciences Announces Fourth Quarter and Full Year 2021 Financial Results | BU |
02/01 | U.s. fda approves new label update for car t-cell therapy yescarta showing prophylactic.. | AQ |
01/31 | U.S. FDA Approves New Label Update for CAR T-Cell Therapy Yescarta® Showing Prophylacti.. | BU |
01/31 | Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination.. | AQ |
01/25 | Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination.. | BU |
01/24 | Gilead Sciences-FDA Approves Veklury (Remdesivir) for the Treatment of Non-Hospitalized.. | AQ |
01/21 | FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at Hi.. | BU |
01/19 | GILEAD SCIENCES : Announces Actions to Remove Counterfeit HIV Medications from U.S. Supply.. | PU |